Sionna Therapeutics showcases novel CFTR stabilizers at NACFC 2023
At the forefront of cystic fibrosis research, Sionna Therapeutics recently unveiled critical preclinical findings on their innovative Series 2 NBD1 stabilizers at the 2023 North American Cystic Fibrosis Conference. The company’s stabilizers, SION-719 and SION-451, have demonstrated the potential to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in preclinical […]